NCT06809595Phase 3Active not recruiting

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

Study sponsor: Definium Therapeutics US, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-08-13Actual
Enrollment · participants245Actual
Source updated2026-09-04Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Aug 2026. After: 13 Aug 2026.

Check registry source

· 1 field changed

Primary completion date changed

Before: Nov 2026. After: Aug 2026.

Check registry source

· 2 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 250 participants (planned). After: 245 participants (actual).

Check registry source

· 1 field changed

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview